Clinical trial success for new cancer drug for patients with same faulty gene as Angelina Jolie
A new cancer drug for patients with the same faulty gene as actress Angelina Jolie has shown ‘impressive responses’ in a clinical trial, researchers have said.
The potential drug, called BMN 673, targets DNA repair in cancer cells and is designed to attack tumours that have been left vulnerable by genetic mutations.
BRCA genes were brought into the public consciousness last month after Jolie, 37, revealed she underwent a double mastectomy when doctors told her that her faulty gene – BRCA1 – meant she had an 87 per cent risk of developing breast cancer and a 50 per cent risk of ovarian cancer.
Scientists studying BMN…
View original post 415 more words